AR123569A1 - Conjugados de pirrolobenzodiazepina-anticuerpo y usos de los mismos - Google Patents

Conjugados de pirrolobenzodiazepina-anticuerpo y usos de los mismos

Info

Publication number
AR123569A1
AR123569A1 ARP210102628A ARP210102628A AR123569A1 AR 123569 A1 AR123569 A1 AR 123569A1 AR P210102628 A ARP210102628 A AR P210102628A AR P210102628 A ARP210102628 A AR P210102628A AR 123569 A1 AR123569 A1 AR 123569A1
Authority
AR
Argentina
Prior art keywords
formula
pyrrolobenzodiazepine
antibody conjugates
antibody
residue
Prior art date
Application number
ARP210102628A
Other languages
English (en)
Inventor
Berkel Patricius Hendrikus Cornelis Van
Persis Amrolia
Kerry Chester
Jenny Yeung
Original Assignee
Adc Therapeutics Sa
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adc Therapeutics Sa, Medimmune Ltd filed Critical Adc Therapeutics Sa
Publication of AR123569A1 publication Critical patent/AR123569A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación se refiere a nuevos conjugados anticuerpo-fármaco de pirrolobenzodiazepina (PBD-ADC) y usos terapéuticos de los mismos. Reivindicación 1: Un conjugado de fórmula (1): Ab - (DL)ₚ (1) en donde: Ab es un anticuerpo que se une a CD45; y DL es DLb: de fórmula (2), en donde X es: un compuesto de fórmula (3), donde a = de 0 a 5, b1 = de 0 a 16, b2 = de 0 a 16, c1 = 0 ó 1, c2 = 0 ó 1, d = de 0 a 5, donde al menos b1 o b2 = 0 y al menos c1 o c2 = 0; GLL es un grupo enlazador conectado a Ab; cuando hay un doble enlace entre C2 y C3, R²² es metilo; cuando hay un enlace simple entre C2 y C3, R²² es H o un resto de fórmula (4); cuando hay un doble enlace entre C2’ y C3’, R³² es metilo; cuando hay un enlace simple entre C2’ y C3’, R³² es H o un resto de fórmula (4); y p es de 1 a 8.
ARP210102628A 2020-09-25 2021-09-22 Conjugados de pirrolobenzodiazepina-anticuerpo y usos de los mismos AR123569A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2015226.0A GB202015226D0 (en) 2020-09-25 2020-09-25 Pyrrol obenzodiazepine-antibody conugates and uses thereof

Publications (1)

Publication Number Publication Date
AR123569A1 true AR123569A1 (es) 2022-12-14

Family

ID=73197359

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102628A AR123569A1 (es) 2020-09-25 2021-09-22 Conjugados de pirrolobenzodiazepina-anticuerpo y usos de los mismos

Country Status (8)

Country Link
US (2) US20220096654A1 (es)
EP (1) EP4217008A1 (es)
JP (1) JP2023542412A (es)
CN (1) CN116940386A (es)
AR (1) AR123569A1 (es)
GB (1) GB202015226D0 (es)
TW (1) TW202228787A (es)
WO (1) WO2022063853A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024064771A1 (en) * 2022-09-20 2024-03-28 Vor Biopharma Inc. Anti-cd45-ign antibody drug conjugates and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB9323199D0 (en) 1993-11-10 1994-01-05 Falkenberg J H F Leukaemia treatment
US20050288491A1 (en) 2004-02-17 2005-12-29 Wilson David S Super-humanized antibodies against respiratory syncytial virus
EP1844074B1 (en) 2005-02-03 2013-04-24 Antitope Limited Human antibodies and proteins
EP1934174B1 (en) 2005-10-07 2011-04-06 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
CA2729961C (en) * 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Li113, li62 variant co2, anti-lingo antibodies
US8529150B2 (en) * 2009-09-23 2013-09-10 Richard Carl Olson Toothbrush device
KR101819404B1 (ko) 2012-10-12 2018-02-28 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
FR2997738A1 (fr) * 2012-11-08 2014-05-09 Poolstar Module d'aspiration et refoulement d'un fluide et systeme de traitement dudit fluide associe
KR102066318B1 (ko) * 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
CN107148285B (zh) * 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
EP3280720A4 (en) 2015-04-06 2018-12-05 President and Fellows of Harvard College Compositions and methods for non-myeloablative conditioning
US9513093B1 (en) * 2015-05-11 2016-12-06 Iron Mountain Products, Llc Arrow mounted tracking apparatus
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
RS63502B1 (sr) 2017-04-18 2022-09-30 Medimmune Ltd Konjugati pirolobenzodiazepina
US10812910B2 (en) * 2018-09-14 2020-10-20 Harman International Industries, Incorporated Inverted motor transducer with front spider
CN113302203A (zh) * 2018-10-30 2021-08-24 美真达治疗公司 抗cd45抗体及其缀合物
CA3125751A1 (en) 2019-01-07 2020-07-16 Magenta Therapeutics, Inc. Use of an anti-cd45 antibody drug conjugate (adc) in cell therapy

Also Published As

Publication number Publication date
GB202015226D0 (en) 2020-11-11
US20240269314A1 (en) 2024-08-15
TW202228787A (zh) 2022-08-01
JP2023542412A (ja) 2023-10-06
US20220096654A1 (en) 2022-03-31
EP4217008A1 (en) 2023-08-02
WO2022063853A1 (en) 2022-03-31
CN116940386A (zh) 2023-10-24

Similar Documents

Publication Publication Date Title
MA30162B1 (fr) Nouveaux derives de pyrrole a cycles fusionnes
AR123569A1 (es) Conjugados de pirrolobenzodiazepina-anticuerpo y usos de los mismos
CO6670522A2 (es) Conjugados de anticuerpos multifuncionales de anticuerpos anti-igf1r, derivados de los mismos y composiciones que los contienen
AR046845A1 (es) Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
MA35153B1 (fr) Immunoconjugués, compositions les contenant, et procédés de préparation et d'utilisation correspondants
TR200401755T4 (tr) Metanesulfonamıdo-benzofuran hazırlama metodu ve bunun sentez ara ürünü olarak kullanım şekli
MA33886B1 (fr) Dérivés substitués d'acide carbamoylméthylamino-acétique utilisés comme nouveaux inhibiteurs de nep
WO2001060416A3 (en) Matrix metalloproteinase inhibitors as targeting components in diagnostic agents
PE20020254A1 (es) Derivados de piridina
HUP0301427A2 (hu) Fotokemoterápiában alkalmazható fotoszenzitizáló, 5-aminolevulinsavészterek azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
DK1534342T3 (da) Modificerede saccharider, konjugater deraf og fremstilling deraf
AR048035A1 (es) Conjugados de almidon de hidroxialquilo y una proteina, preparados por aminacion reductora
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
AR065621A1 (es) Derivados de amino-piridina, una composicion farmaceutica que los comprende y su uso como medicamento para el tratamiento de enfermedades asociadas al sistema inmune activado.
BR0316386A (pt) Benzoxazin-3-onas e seus derivados como inibidores de p13k
ES2112650T3 (es) Sales de un derivado de indol antimigraña.
BR0214437A (pt) Composto, composição farmacêutica, métodos de modular um receptor ativado por proliferador de peroxissoma, de tratar e de prevenir a diabete melito, e de tratar a sìndrome x, e doenças cardiovasculares em um mamìfero, e, uso de um composto
AR117657A1 (es) Conjugados de fármaco que comprenden anticuerpos y derivados de ecteinascidina
DK0989972T3 (da) Farmaceutiske prostaglandinsammensætninger
CL2022001642A1 (es) Compuestos adhesivos fotoprotectores y usos de los mismos
DK1327146T3 (da) Forbindelse med et forgrenet linkermolekyle
MA33103B1 (fr) Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met
BR112022014391A2 (pt) Compostos e conjugados dos mesmos
AR118849A1 (es) Conjugado de anticuerpo anti-bcma, composiciones que lo comprenden, y métodos para fabricarlo y usarlo
ATE502922T1 (de) Matrix-metalloproteinaseinhibitoren

Legal Events

Date Code Title Description
FB Suspension of granting procedure